FactorPlus — The Helixate® FS Free Hemophilia A Treatment Trial Program

Get connected to treatment that meets a patient’s unique needs with FactorPlus

With FactorPlus — the Helixate FS free trial program — patients can try out a recombinant FVIII treatment for hemophilia A at no cost.

  • When a patient signs up for FactorPlus, he or she is eligible to receive 6 doses, or up to 20,000 IU, of Helixate FS
  • Helixate FS is an effective and safe recombinant FVIII hemophilia A treatment with a wide range of dosages and concentrations
    • The recently introduced Helixate FS 3000 IU dosage strength makes it possible for some patients to infuse without using multiple vials during major bleeding episodes
  • The FactorPlus Welcome Kit provides a comprehensive overview of hemophilia A and its treatment

Use FactorPlus to see if Helixate FS is the right choice.

FactorPlus is just one of our innovative patient programs

Starting a free trial of Helixate FS with FactorPlus does more than give the patient access to a recombinant treatment for hemophilia A. FactorPlus also puts the patient in touch with CSL Behring's innovative, community-building programs, including:

  • Gettin' in the GameSM (GIG)
  • The GIG Junior National Championships
  • Hemophilia MomsSM and Mom2MomSM
  • Common FactorsSM

3 easy steps enroll in FactorPlus today

Healthcare professionals will enroll patients in the FactorPlus so that they can begin their free trial of Helixate FS. Here's how:

  1. Patients can bring the trial product request form to their next doctor's appointment.
  2. Patients can share the form with their doctor and discuss whether Helixate FS is right for them or their loved one for hemophilia A treatment.

Patients should ask their doctor to complete the form and send it in for processing

Next: Healthcare Professional Resources»

Important Safety Information

Helixate® FS, Antihemophilic Factor (Recombinant), is a recombinant factor VIII treatment indicated for the control and prevention of bleeding episodes and peri-operative management in adults and children (0-16 years) with hemophilia A. Helixate® FS is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A with no preexisting joint damage.

The most serious adverse reactions are systemic hypersensitivity reactions and the development of high-titer inhibitors necessitating alternative treatments to antihemophilic factor. The most common adverse reactions observed in clinical trials were inhibitor formation in previously untreated or minimally treated patients, skin-associated hypersensitivity reactions, infusion site reactions, and central venous access device (CVAD) line-associated infections.

Helixate® FS is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including mouse or hamster proteins.

Please see the full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.